Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:4 Number:24 ISSN#:2563-5476
ACE Report #2736
Ace Report Cover Arthroplasty

Rivaroxaban offers effective extended thromboprophylaxis than enoxaparin after THA

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial

Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24

Contributing Authors: Ajay K Kakkar Benjamin Brenner Ola E Dahl Bengt I Eriksson Patrick Mouret Jim Muntz Andrea G Soglian Ákos F Pap Frank Misselwitz Sylvia Haas for the RECORD2 Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


2509 patients (>18 yr old) scheduled to undergo elective total hip arthroplasty were randomized to receive either oral rivaroxaban or enoxaparin to compare both methods of thromboprophylaxis. After a 42 day follow up, extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptoma...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.